Long-term safety and efficacy of intravenous administration of an AAV8 vector-expressing factor IX in patients with haemophilia B has recently been demonstrated [17], but the development of a gene therapy-based treatment for haemophilia A has, in part, be hindered by the large size of the factor (F) VIII cDNA. Here, F9 is linked to hemophilia A.